Aspen Pharmacare Current Ratio 2017-2025 | APNHY
Aspen Pharmacare current ratio from 2017 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Aspen Pharmacare Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-12-31 | $3.35B | $0.92B | 3.64 |
| 2025-06-30 | $2.13B | $0.96B | 2.21 |
| 2024-12-31 | $2.26B | $0.96B | 2.35 |
| 2024-06-30 | $2.36B | $1.30B | 1.81 |
| 2023-12-31 | $2.35B | $1.23B | 1.92 |
| 2023-06-30 | $2.51B | $1.31B | 1.92 |
| 2022-12-31 | $2.25B | $0.94B | 2.40 |
| 2022-06-30 | $2.27B | $1.54B | 1.48 |
| 2021-12-31 | $2.37B | $1.21B | 1.96 |
| 2021-06-30 | $2.13B | $2.40B | 0.89 |
| 2020-12-31 | $2.79B | $1.29B | 2.16 |
| 2020-06-30 | $2.37B | $1.16B | 2.03 |
| 2019-06-30 | $2.55B | $1.41B | 1.80 |
| 2018-12-31 | $3.17B | $1.55B | 2.05 |
| 2018-06-30 | $3.14B | $2.20B | 1.43 |
| 2017-12-31 | $2.65B | $2.97B | 0.89 |
| 2017-06-30 | $2.80B | $2.56B | 1.10 |
| 2016-12-31 | $2.61B | $1.76B | 1.48 |
| 2016-06-30 | $2.58B | $1.46B | 1.76 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $4.248B | $2.065B |
| Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |